Managing Treatment-Related Adverse Effects of Multiple Myeloma: Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN

Multiple myeloma is a cancer of the bone marrow plasma cells that causes the overproduction of monoclonal immunoglobulins, which can lead to organ damage. In this excerpt of the transcript from her nursing continuing professional development (NCPD)-approved activity, Multiple Myeloma: Enhancing Treatment Tolerability, Adherence, and Patient-Centered Care, Beth Faiman, PhD, MSN, APN-BC, AOCN®, FAAN, a nurse practitioner at the Cleveland Clinic Taussig Cancer Institute, discusses strateg...
Continue reading

Tirbanibulin for Actinic Keratosis: George Martin, MD

Recently, the results of two phase 3 trials on tirbanibulin were published in the New England Journal of Medicine. Tirbanibulin was studied in two identically designed double-blind trials as a treatment for actinic keratosis, a precursor of cutaneous squamous-cell carcinoma. Adults with actinic keratosis lesions on their face or scalp received either tirbanibulin 1% ointment or placebo once daily for five consecutive days. Compared with those receiving placebo, patients who received tirbanibulin...
Continue reading

Enfortumab Vedotin for Urothelial Carcinoma: Thomas Powles, MD, MBBS, MRCP

For patients with locally advanced or metastatic urothelial carcinoma, treatment options are limited after progression on chemotherapy and immune checkpoint inhibitors, and survival rates remain low. In the phase 3 EV-301 trial, results of which were recently presented at the American Society of Clinical Oncology (ASCO) Genitourinary Cancers Symposium, enfortumab vedotin demonstrated promising efficacy in this patient population. In this interview with Oncology Data Advisor, Dr. Thomas Powles, D...
Continue reading

Cemiplimab for First-line Treatment of Advanced Non-Small Cell Lung Cancer: Ahmet Sezer, MD

Recently, the FDA granted approval to cemiplimab-rwlc (Libtayo®, Regeneron Pharmaceuticals, Inc.) for the first-line treatment of patients with advanced non-small lung cancer cell (NSCLC) whose tumors express programmed death ligand 1 (PD-L1) in at least 50% of their cells and whose tumors do not have aberrations in epidermal growth factor receptor (EGFR), anaplastic lymphoma kinase (ALK), or C-ROS oncogene 1 (ROS1). In this interview, Ahmet Sezer, MD, Professor in the Department of Medical Onco...
Continue reading

Shifting Paradigm in Treating Metastatic Prostate Cancer: Judd W. Moul, MD, FACS

The management of metastatic prostate cancer has undergone a paradigm shift over the last few years. Landmark trials including CHAARTED and STAMPEDE have provided evidence for using therapies that were previously reserved for castration-resistant prostate cancer for patients with hormone-sensitive prostate cancer. In this excerpt of the transcript from his continuing medical education (CME)-approved activity, Clinical Updates and Expert Guidance in Prostate Cancer, Dr. Judd Moul, a urologist at ...
Continue reading


Get the latest updates delivered to your inbox!

Follow Us

Copyright © 2021 Oncology Data Advisor. All rights reserved.